Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab Pre- and Post-ASCT in Multiple Myeloma
NCT04230031Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jul 2021
- Primary completion
- Jan 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Wake Forest University Health Sciences. Primary endpoint: Complete Response Rate Post-ASCT. Planned start Jul 2021; status: withdrawn.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04230031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04230031.